Reports of Practical Oncology and Radiotherapy最新文献

{"title":"An Inpatient Metastatic Spine Neoplasm Score for assessing the appropriate modality of radiation therapy intervention.","authors":"Shearwood McClelland","doi":"10.5603/rpor.101991","DOIUrl":"10.5603/rpor.101991","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"527-529"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Debulking surgery prior to stereotactic radiotherapy for head and neck paragangliomas.","authors":"Geovanne Pedro Mauro, Leila Maria Da Roz, Vinicius de Carvalho Gico, Eduardo Weltman, Evandro César De Souza, Helena Espindola Baraldi, Eberval Gadelha Figueiredo, Carlos Gilberto Carlotti","doi":"10.5603/rpor.101802","DOIUrl":"10.5603/rpor.101802","url":null,"abstract":"<p><strong>Background: </strong>Surgery has been used as standard treatment for head and neck paragangliomas. Stereotactic radiotherapy (SRT) has also been increasingly used for this disease. The results for combined modality are not well described. This analysis aims to describe the results for combined modality of debulking surgery and SRT for head and neck paragangliomas (HNP).</p><p><strong>Materials and and methods: </strong>Retrospective cohort of patients treated in a large university hospital between 2008 and 2023.</p><p><strong>Results: </strong>Fifty-one patients had their charts reviewed. Mean age was 56.3 years. Most were female (82.3%). Most lesions arose from the skull-base (84.3%) and not the inner ear. Most lesions were larger than 3 cm (51.0%) and mean lesion size was 4.4 cm. 36 (70.6%) were treated with radiotherapy alone while 15 (29.4%) were treated with combined modality treatment. Median follow-up was 42.5 months (7.1-112.8 months). There were no reported deaths nor disease progression. Debulking surgery did not impact response rate for SRT (52.8% <i>vs</i>. 47.2% for SRT alone and debulking surgery, respectively, p = 0.971). There was no impact on new neurological deficits after SRT (25.0 <i>vs</i>. 13.3%, respectively, p = 0.356).</p><p><strong>Conclusion: </strong>Debulking surgery did not improve response rate for SRT. In our sample, it also did not impact new neurological deficits for SRT. Prospective data regarding HNP treatment is needed.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"454-459"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer.","authors":"Marta Lopez-Valcarcel, Francisco J Valcarcel, Joaquin Velasco, Irma Zapata, Ruth Rodriguez, Jorge Cardona, Beatriz Gil, Sofia Cordoba, Raquel Benlloch, Maria Hernandez, Sofia Santana, Ricardo Gomez, Cristina De la Fuente, M Isabel Garcia-Berrocal, Carlos Regueiro, Jesus Romero","doi":"10.5603/rpor.101528","DOIUrl":"10.5603/rpor.101528","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the clinical outcomes of stereotactic ablative radiotherapy (SABR) in the treatment of oligometastatic pelvic node prostate cancer to delay androgen deprivation therapy (ADT).</p><p><strong>Materials and methods: </strong>Pelvic lymph node metastases were identified by ¹¹C-choline positron emission tomography (PET)-computed tomography (CT), and patients were not receiving ADT. SABR was administered using linear accelerators with intensity-modulated and image-guided radiotherapy, at a prescribed dose of 35 Gy in 5 fractions over 2 weeks. Response was assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, and prostate-specific antigen (PSA) levels were monitored post-SABR. Toxicity and quality of life were assessed by the Common Terminology Criteria for Adverse Events Toxicity (CTCAE) v.5.0 and European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires QLQ-C30/QLQ-PR25, respectively. Kaplan-Meier and T-test were used for statistical analysis.</p><p><strong>Results: </strong>Between June 2015 and November 2023, 56 patients with 85 lesions were treated at our institution. Median follow-up was 30 months [95% confidence interval (CI): 24-33.6]. Prostatectomy was the radical treatment in 85.7% of patients, and radiotherapy in 14.3%. Response rates were 67.1% for complete response, 27.4% for partial response, and 1.4% for stable disease. In-field progression was observed in only 3 lesions (3.5%). The median time to biochemical relapse post-SABR was 15 months (95% CI: 11.4-18.6). Three-year pelvic nodal and distant progression-free survival were 62.5% and 80%, respectively. There was a significant decrease in PSA levels after SABR compared to pretreatment levels (0.77 <i>vs</i>. 2.16 ng/mL respectively, p = 0.001). No grade ≥ 2 genitourinary or gastrointestinal toxicities. The median global health status score was 83.33 points at both time points analysed.</p><p><strong>Conclusion: </strong>SABR can delay the ADT and provide excellent local control while preserving quality of life.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"445-453"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity in biological response of MDA-MB-231 cells after proton irradiation along different parts of the depth-dose curve: before, within, and behind the Bragg peak.","authors":"Marika Musielak, Kinga Graczyk, Małgorzata Liszka, Eleftherios Papalanis, Wiktoria Suchorska, Tomasz Piotrowski, Bo Stenerlöw, Julian Malicki","doi":"10.5603/rpor.102129","DOIUrl":"10.5603/rpor.102129","url":null,"abstract":"<p><strong>Background: </strong>Proton therapy has garnered attention as an advanced radiation treatment modality for breast cancer due to its ability to deliver highly precise doses to the target area while minimizing exposure to surrounding healthy tissues. The aim was to detect potential variations in radiobiological response along different parts of the proton depth-dose curve.</p><p><strong>Materials and methods: </strong>MDA-MB-231 cells were specifically irradiated before, within, and beyond the Bragg peak with a 5 Gy dose, with photons used as a reference. The radiobiological response was evaluated using clonogenic assays, relative γH2AX levels, and quantitative polymerase chain reaction (qPCR) analysis of DNA damage response genes.</p><p><strong>Results: </strong>A trend of increasing magnitude in radiobiological response was observed with increasing depth of cell irradiation, accompanied by a decrease in survival fraction. Furthermore, differences were noted, particularly in γH2AX levels along the Bragg peak, with higher values of DNA double-strand breaks (DNA DSB) observed at the end of the depth-dose curve.</p><p><strong>Conclusions: </strong>These findings suggest that despite administering a consistent proton dose to the target area, there can be a range of different biological reactions, which might have significant indications for clinical procedures.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"478-487"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of educational services by Patient Target Group participating in the National Skin Cancer Prevention Programme (OPPNS) based on the example of the Wielkopolska region.","authors":"Agnieszka Dyzmann-Sroka","doi":"10.5603/rpor.100776","DOIUrl":"10.5603/rpor.100776","url":null,"abstract":"<p><strong>Background: </strong>Skin melanoma is one of the three main types of skin cancer along with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), and develops from melanocytes. 2019 saw the beginning of the National Skin Cancer Prevention Programme (OPPNS) in Poland. One of the tasks performed was a health promotion campaign for patients. To effectively educate the public, the project was preceded by a survey assessing knowledge on skin cancer prevention methods. Then, the survey was repeated to evaluate the effectiveness of the awareness raising campaign.</p><p><strong>Materials and methods: </strong>both studies were conducted based on an author-developed survey. A representative sample size was determined based on the calculator available at www.cem.pl/pl/analizy/wielkość-proby. In addition, each participant filled in a knowledge upgrade declaration. The analysis employed basic statistical data, such as absolute numbers and structural indicators.</p><p><strong>Results and conclusions: </strong>Knowledge upgrade score of 9.16 (out of 10) was declared by 99.7% of the respondents. As many as 99.0% of them declared an intent to change their lifestyle to a healthier one. Thus, the education provided to the Programme participants was confirmed to have raised their awareness of skin cancer prevention and self-examination methods.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"294-299"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature.","authors":"Ankita Mehta, Rohit Avinash Vadgaonkar, Shirley Lewis, Umesh Mahantshetty, J P Agarwal","doi":"10.5603/rpor.100777","DOIUrl":"10.5603/rpor.100777","url":null,"abstract":"<p><strong>Background and objectives: </strong>Despite decades of experience with definitive chemo-radiotherapy (CRT) in cervical oesophageal cancer (CEC), the loco-regional control and survival outcomes are dismal. This review evaluated the outcomes of various treatment strategies being commonly utilized.</p><p><strong>Materials and methods: </strong>A literature review was conducted to identify relevant articles on CEC published from years 2000-2023 addressing the predefined key questions. These questions focussed on the comparative outcomes of various primary treatment approaches (surgery, CRT, or trimodality treatment) and the radiation dose schedules, volumes, and techniques.</p><p><strong>Results: </strong>CRT is the standard approach for treatment for CEC so far. The potential role of surgery and trimodality approach in settings of evolving surgical approaches needs to be validated. The high dose schedules that are preferentially practiced in CEC have not shown any benefit in improving the disease outcomes over the standard dose schedule of 50.4 Gy. The target volume delineation practice of elective nodal irradiation (ENI) does not have a proven benefit over the involved field irradiation (IFI). The limited evidence on radiation techniques suggests that intensity-modulated radiotherapy/volumetric-modulated arc therapy (IMRT/VMAT) techniques can improve toxicity profile over three-dimensional conformal radiotherapy (3DCRT), but no advantage proven in disease outcomes so far.</p><p><strong>Conclusion: </strong>This review will guide clinicians in decision-making for the management of this relatively rare entity and the directions for future research in these areas. Future large-scale multicentre prospective studies are needed for validating and standardizing our current practices and exploring potential options to improve the outcomes.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"391-408"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forecasting model for qualitative prediction of the results of patient-specific quality assurance based on planning and complexity metrics and their interrelations. Pilot study.","authors":"Tomasz Piotrowski, Adam Ryczkowski, Petros Kalendralis, Marcin Adamczewski, Piotr Sadowski, Barbara Bajon, Marta Kruszyna-Mochalska, Agata Jodda","doi":"10.5603/rpor.101093","DOIUrl":"10.5603/rpor.101093","url":null,"abstract":"<p><strong>Background: </strong>The purpose was to analyse the interrelations between planning and complexity metrics and gamma passing rates (GPRs) obtained from VMAT treatments and build the forecasting models for qualitative prediction (QD) of GPRs results.</p><p><strong>Materials and method: </strong>802 treatment arcs from the plans prepared for the head and neck, thorax, abdomen, and pelvic cancers were analysed. The plans were verified by portal dosimetry and analysed twice using the gamma method with 3%|2mm and 2%|2mm acceptance criteria. The tolerance limit of GPR was 95%. Red, yellow, and green QDs were established for GPR examination. The interrelations were examined, as well as the analysis of effective differentiation of QD. Three models for QD forecasting based on discriminant analysis (DA), random decision forest (RDF) methods, and the hybrid model (HM) were built and evaluated.</p><p><strong>Results: </strong>Most of the interrelations were small or moderate. The exception is correlations of the join function with the average number of monitor units per control point (R = 0.893) and the beam aperture with planning target volume (R = 0.897). While many metrics allow for the effective separation of the QDs from each other, the study shows that predicting the values of the QD is possible only through multi-component forecasting models, of which the HM is the most accurate (0.894).</p><p><strong>Conclusion: </strong>Of the three models explored in this study, the HM, which uses DA methods to predict red QD and RDF methods to predict green and yellow QDs, is the most promising one.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"318-328"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose escalation with simultaneous integrated boost for un-methylated multiple glioblastoma.","authors":"Ory Haisraely, Maayan Sivan, Zvi Symon, M Ben-Ayun, L Tsvang, J Kraitman, S Dubinsky, M Siman-Tov, D Benjamin, Yaacov Lawrence, Zvi Cohen, Anton Wohl, Thila Kaisman-Elbaz, Alisa Taliansky","doi":"10.5603/rpor.100385","DOIUrl":"10.5603/rpor.100385","url":null,"abstract":"<p><strong>Background: </strong>Simultaneous involvement of multiple distinct brain regions occurs in 2-5% of all high-grade gliomas (HGG) and is associated with poor prognosis. Whereas radiotherapy (RT) is an important and well-established treatment for high-grade glioma, the role of dose-escalated radiotherapy has yet to be established. In this case series, we report upon the dosimetry, adverse effects, and response in patients with multiple un-methylated high-grade gliomas receiving dose-escalated radiation.</p><p><strong>Materials and methods: </strong>We reviewed charts of patients with multifocal high grade glioma treated at our institution since January 2022. All patients had stereotactic biopsies after an magnetic resonance imaging (MRI) contrast-enhanced with T1, T2, FLAIR sequences and were discussed in a multidisciplinary oncology team. MGMT-positive patients received either TMZ alone or RT with TMZ and were excluded from this analysis. Un-methylated patients received dose-escalated RT without temezolamide (TMZ). Following computed tomography (CT) and MR simulation, the gros tumor volume (GTV) was delineated and prescribed 52.5 Gy in 15 fractions within the standard 40.05 Gy planning treatment volume (PTV). Treatment planning was volumetric modulated arc therapy.</p><p><strong>Results: </strong>A total of 20 patients with multiple un-methylated MGMT glioblastoma multiforme were treated with dose-escalated radiation therapy between January 2022 and June 2023. All patients completed dose escalated radiotherapy without acute adverse effects. Progression-free survival at six months was 85%, as defined by the RANO criteria.</p><p><strong>Conclusion: </strong>In this case series, we showed that un-methylated multiple high-grade glioma could be safely treated with dose escalation. Results of progression-free survival should be validated in a larger prospective clinical trial.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"290-293"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!","authors":"Kamel Debbi, Gokoulakrichenane Loganadane, Louise Roulin, Karim Belhadj, Chahrazed Boukhobza, Amira Saoudi, Noémie Grellier, Yazid Belkacemi","doi":"10.5603/rpor.100780","DOIUrl":"10.5603/rpor.100780","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"409-411"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of model-based dose-calculation algorithms in high dose rate brachytherapy of cervical carcinoma.","authors":"Shraddha Srivastava, Ajay Kannathuparambil Venugopal, Moirangthem Nara Singh","doi":"10.5603/rpor.100778","DOIUrl":"10.5603/rpor.100778","url":null,"abstract":"<p><strong>Background: </strong>Task Group 43 (TG-43) formalism does not consider the tissue and applicator heterogeneities. This study is to compare the effect of model-based dose calculation algorithms, like Advanced Collapsed Cone Engine (ACE), on dose calculation with the TG-43 dose calculation formalism in patients with cervical carcinoma.</p><p><strong>Materials and methods: </strong>20 patients of cervical carcinoma treated with a high dose rate of intracavitary brachytherapy were prospectively studied. The target volume and organs at risk (OARs) were contoured in the Oncentra treatment planning system (Elekta, Veenendaal, The Netherlands). All patients were planned with cobalt-60 (Co-60) and iridium-192 (Ir-192) sources with doses of 21 Gy in 3 fractions. These plans were calculated with TG-43 formalism and a model-based dose calculation algorithm ACE. The dosimetric parameters of TG-43 and ACE-based plans were compared in terms of target coverage and OAR doses.</p><p><strong>Results: </strong>For Co-60-based plans, the percentage differences in the D90 and V100 values for high-risk clinical target volume (HR-CTV) were 0.36 ± 0.43% and 0.17 ± 0.31%, respectively. For the bladder, rectum and sigmoid, the percentage differences for D2cc volumes were -0.50 ± 0.51%, -0.16 ± 0.53% and -0.37 ± 1.21%, respectively. For Ir-192-based plans, the percentage difference in the D90 for HR-CTV was 0.54 ± 0.79%, while V100 was 0.24 ± 0.29%. For the bladder, rectum and sigmoid, the doses to 2cc volume were 0.35 ± 1.06%, 0.99 ± 0.74% and 0.74 ± 1.92%, respectively. No significant differences were found in the dosimetric parameters calculated with ACE and TG-43.</p><p><strong>Conclusion: </strong>The ACE algorithm reduced doses to OARs and targets. However, ACE and TG-43 did not show significant differences in the dosimetric parameters of the target and OARs with both sources.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 3","pages":"300-308"},"PeriodicalIF":1.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}